

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/763,904	
	ATION DISC			Filing Date	January 23, 2004	
STATEMENT BY APPLICANT (use as many sheets as necessary)				First Named Inventor	Pascal Druzgala	
				Art Unit	not yet assigned	
·				Examiner Name	not yet assigned	
Sheet	1	of	2	Attorney Docket Number	ARYX-101XCD2	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant . of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant ; Figures Appear		
M	U1	US-4,634,707 A	01-06-1987	Brewer	All		
IM	U2	US-6,387,914 B2	05-14-2002	Druzgala et al.	: All		
M	U3	US-6,683,086 B2	01-27-2004	Druzhala et al. i.	: All		
	U4	US-		ê	1		
	U5	US-		\$.	;		

		FOREIGN	PATENT DOCU	JMENTS		
		Foreign Patent Document		:	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials*	Cite No. ¹	Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		T ⁶
\/h	F1	CH 678394 A5	09-13-1992	Cerny, E.	All	
M	F2	WO 98/58925	12-30-1998	Boehringer	All	
M	F3	WO 93/20064	10-14-1993	Biosite Diagnostics	All	
ad,	F4	WO 91/08191	06-13-1991	Sloan-Kettering Inst.	All	
Ŵ	F5	FR 2 300 568 A	09-10-1976	SFOFA	All	
CY	F6	DE 24 05 732 A	08-21-1975	Bayer	All	
	F7					
	F8					
	F9					

	, , , = , = , , , , , , , , , , , , , ,		
Examiner	$1 \wedge C \wedge $	Date	14/010/0
Signature	1. V. Dalesul owend	Considered	1812104
Signature		Odrisidered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradernark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

*Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

2

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Con	nplete if Known	
Application Number	10/763,904	
Filing Date	January 23, 2004	
First Named Inventor	Pascal Druzgala	_
Group Art Unit	not yet assigned	
Examiner Name	not yet assigned	
Attorney Docket Number	ARYX-101XCD2	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
M	R1	Chemical Abstracts, Vol. 95, no. 7, 1981, page 42, Columbus, Ohio, US; abstract no. 54821y.			
M	R2	Chemical Abstracts, Vol. 97, no. 1, 1982, page 13, Columbus, Ohio, US; abstract no. 16559c.			
M	R3	Chemical Abstracts, Vol. 100, no. 28, July 30, 1993, page 603, Columbus, Ohio, US; abstract no. 68316w.			
\mathbb{W}	R4	Chemical Abstracts, Vol. 126, no. 17, 1997, Columbus, Ohio, US; abstract no. 225269q, Abdel-Hamide , page 575			
M	R5	MIREK, J. (1978) "Syunthesis A. Pharmacolgical Screening of Some N-Carboxymethylbarbituric Acid Derivatives 1" Pol. J. Pharmacol. 30:685-693.			
5	R6	PORTER, R.J., MELDRUM, B.S. (1992) "Antiepileptic drugs" Basic & Clinical Pharmacology, Katzung B.G., Ed., Appleton & Lange, Norwalk, Conn., 5 th Edition, pp. 331-349.			
8	R7	TREVOR, A.J., WAY, W.L. (1992) "Sedative-hypnotics" Basic & Clinical Pharmacology, Katzung B.G., Ed., Appleton & Lange, Norwalk, Conn., 5 th Edition, pp. 306-319.			
	R8				
	R9				
	R10				
-	R11.				
	R12				
	R13				

	Examiner \ \ Signature	^.	Balesutromain	Date Considered	4/2/04
--	----------------------------	----	---------------	--------------------	--------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.